Heart Disease Trial, Recruiting NCT05897632 Sponsor: Wake Forest University Health Sciences Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05897632
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 21 years or older
  • People experiencing chest pain or other symptoms that could suggest a possible heart attack
  • People whose risk score for a heart attack (called a HEART score) falls between 4 and 6, indicating a moderate level of risk
  • People whose heart tracing (ECG) does not show signs of reduced blood flow to the heart
  • People whose two blood test results measuring heart muscle protein (troponin) are both below the normal upper limit for their sex (below 15 pg/ml for women, below 20 pg/ml for men)
  • People with no previous history of coronary artery disease, including no prior heart attack, no prior procedures to open or bypass blocked heart arteries, and no known blockages of 70% or more in the heart arteries

Who may not be able to join:

  • People who are having a major type of heart attack called an ST Elevation Myocardial Infarction (STEMI)
  • People whose ECG (heart tracing) shows certain concerning changes, such as significant ST changes or new T-wave inversions of 1mm or more
  • People who have any troponin (heart protein) blood test result that is above the normal upper limit for their sex
  • People whose two troponin blood test results differ from each other by 5 pg/mL or more
  • People who have had certain heart tests — including a stress echocardiogram, nuclear stress test, stress ECG, stress cardiac MRI, CT scan of the heart arteries, or an invasive heart artery procedure — within the past year
  • People who have had a heart artery scan or invasive procedure in the past two years that showed completely clear arteries (0% blockage in all vessels)
  • People whose chest symptoms are due to a physical injury to the chest
  • People who are pregnant
  • People whose life expectancy is estimated to be less than one year
  • People who have other serious health conditions that require hospital admission
  • People with unstable vital signs, including very low blood pressure (below 90), very fast or very slow heart rate (above 120 or below 50 beats per minute), or low blood oxygen levels (below 90%)
  • People with severe kidney disease, including those on dialysis or with a kidney function measurement (eGFR) below 30 mL/min
  • People being transferred from another hospital
  • People who do not speak English
  • People who are currently in prison
  • People who have previously taken part in this trial
  • People who are already enrolled in another interventional clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Simon Mahler, MD, MS, Wake Forest University Health Sciences

Phone: 336-716-4646

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 October 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hospital-free days (HFD) at 30-days post-randomization

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov